Zhang X H, Lowe D, Giles P, Fell S, Connock M J, Maslin D J
Division of Biomedical Sciences and Human Biology, School of Health Sciences, University of Wolverhampton, Wolverhampton WV1 1DJ, UK.
J Nutr. 2001 May;131(5):1471-8. doi: 10.1093/jn/131.5.1471.
Early trials of garlic preparations on blood lipids mainly supported a lipid-lowering effect, whereas later well-designed garlic tablet trials were mainly entirely null. However, enteric simulation tests suggest that this discordance may result from ineffective delivery of bioactive agents from the brands of garlic powder (GP) and cyclodextrin-bound garlic oil (GO) tablets tested in some recent negative trials. In contrast, enteric simulation tests show that the preformed bioactive agents present in "traditional" gelatin capsules of GO are efficiently released, although such capsules have rarely been investigated in lipid-lowering trials. It was hypothesized that gelatin capsules of GO given to normal subjects would improve specified coronary heart disease risk factors. Effects of a GP preparation were also investigated. Subjects (n = 51; men and women, mean age 27 y) were randomly assigned to receive either 8.2 mg/d of GO (allyl sulfides) or placebo for 11 wk. Another 27 subjects received garlic powder (GP) of similar biopotential (7.8 mg allicin/d). Outcome measures were 95% confidence intervals (CI) between GO and placebo groups for differences between baseline and subsequent sample times. Men and women combined showed no significant differences save for an improved total antioxidant capacity at 6 wk (P = 0.01). Hence, no benefit from GO after 11 wk is one plausible conclusion. However, there were significant differences in effect of GO between men and women for HDL cholesterol (HDL-C) (P = 0.004) and total cholesterol (TC)/HDL-C (P = 0.003). Women showed favorable effects in terms of CHD risk factors (i.e., increases in HDL-C and reductions in TC/HDL-C), whereas men had small adverse effects. There was a significant difference in the GO effect for glucose (P = 0.006), with a reduction seen for men and an increase for women. The gender effects were unexpected and such analyses were not planned in advance. Confirmation of these findings with larger numbers of subjects would have importance for the use of garlic against CHD and for the design of future garlic studies.
早期关于大蒜制剂对血脂影响的试验主要支持其具有降脂作用,而后来设计良好的大蒜片试验大多完全没有得出这样的结果。然而,肠内模拟试验表明,这种不一致可能是由于在一些近期的阴性试验中所测试的大蒜粉(GP)品牌和环糊精结合大蒜油(GO)片的生物活性剂递送无效所致。相比之下,肠内模拟试验表明,GO“传统”明胶胶囊中预先形成的生物活性剂能有效释放,尽管这种胶囊在降脂试验中很少被研究。据推测,给正常受试者服用GO明胶胶囊会改善特定的冠心病危险因素。同时也研究了一种GP制剂的效果。受试者(n = 51;男性和女性,平均年龄27岁)被随机分配接受每日8.2毫克的GO(烯丙基硫化物)或安慰剂,为期11周。另外27名受试者接受了具有相似生物活性的大蒜粉(GP)(每日7.8毫克大蒜素)。结果测量指标是GO组和安慰剂组之间基线与后续采样时间差异的95%置信区间(CI)。男性和女性合并来看,除了在6周时总抗氧化能力有所改善(P = 0.01)外,没有显著差异。因此,11周后服用GO没有益处是一个合理的结论。然而,男性和女性在GO对高密度脂蛋白胆固醇(HDL-C)(P = 0.004)和总胆固醇(TC)/HDL-C(P = 0.003)的影响上存在显著差异。女性在冠心病危险因素方面显示出有利影响(即HDL-C升高和TC/HDL-C降低),而男性则有较小的不利影响。GO对血糖的影响存在显著差异(P = 0.006),男性血糖降低,女性血糖升高。这种性别效应出乎意料,而且此类分析并非预先计划好的。用更多受试者证实这些发现对于大蒜在预防冠心病方面的应用以及未来大蒜研究的设计具有重要意义。